Azathioprine Therapy in Refractory ITP

Introduction to Azathioprine

• The American College of Hematology recommends azathioprine as a second-line therapy option for refractory ITP patients who have failed first-line treatments, with an expected complete response rate of approximately 45% when administered at 150 mg/day for a median of 18 months 1

Positioning in Treatment Algorithm

• Azathioprine is classified as a second-line therapy alongside rituximab, splenectomy, and thrombopoietin receptor agonists, according to the 2010 international consensus guidelines 1
• The international consensus guidelines from Blood position azathioprine primarily as part of combination chemotherapy regimens rather than as monotherapy for third-line treatment in patients failing both first- and second-line approaches 2, 3, 4

Dosing and Administration

• Standard dosing is 1-2 mg/kg daily (maximum 150 mg/day), with a median treatment duration of 18 months 1
• The drug should be started at 150 mg/day orally, which can be adjusted based on response and tolerability 1
• Screening for thiopurine methyltransferase (TPMT) deficiency is necessary if cytopenias develop, as approximately 0.25% of the population lacks this enzyme 1

Expected Response and Timeline

• Complete response (platelet count >100,000/μL) occurs in approximately 45% of patients 1
• Response to azathioprine is characteristically slow, requiring 3-6 months of continuous administration before determining efficacy 1

Safety Profile

• Azathioprine has a relatively favorable safety profile with generally mild side effects, particularly compared to other immunosuppressive options 1
• Leucopenia is a common adverse event, followed by anemia, and hepatobiliary laboratory abnormalities (transaminase elevations up to 3x normal) occur in some patients 1

Combination Therapy Approach

• For patients failing both first- and second-line monotherapies, azathioprine can be incorporated into combination chemotherapy regimens, achieving a 68% overall response rate including 42% complete response in 31 patients 2, 3, 4

Comparison to Other Third-Line Options

• TPO receptor agonists (eltrombopag, romiplostim) have superior response rates (70-88%) and faster response times (1-4 weeks) but require continuous administration and are significantly more expensive 2, 3, 4
• Azathioprine monotherapy offers a more favorable safety profile than combination chemotherapy, making it particularly suitable for patients requiring long-term therapy 1